Status:
COMPLETED
Short-term Dual Antiplatelet Therapy After Deployment of Bioabsorbable Polymer Everolimus-eluting Stent
Lead Sponsor:
Gangnam Severance Hospital
Conditions:
Coronary Artery Disease
Eligibility:
All Genders
19-85 years
Phase:
NA
Brief Summary
To compare the clinical outcomes of P2Y12 antagonist monotherapy with aspirin plus P2Y12 antagonist following 3-month of DAPT in patients undergoing PCI with bioabsorbable polymer Everolimus-eluting s...
Eligibility Criteria
Inclusion
- Age 19+
- Patients treated with a new generation of Evelorimus-eluting stents (Synergy®)
- Patients who understand the content of the subject description and voluntarily sign the subject
Exclusion
- Age 86+
- Hemodynamically unstable patient
- Severe hypersensitivity reactions to aspirin, clopidogrel, ticagrelor, everolimus, contrast agent
- Patients at high risk of bleeding, anemia, thrombocytopenia
- Patients requiring oral anticoagulants
- Pregnant women or women of childbearing age
- Life expectancy is less than one year
- Patients receiving a potent CYP3A4 inhibitor (eg, ketoconazole, clarithromycin, napjodone, ritonavir, atazanavir)
- Patients with a history of intracranial hemorrhage
- Patients with moderate to severe hepatic impairment
- Patients underwent coronary intervention with stenting within 1 year
- Patients with left-main lesions requiring coronary intervention
- Patients with chronic stricture lesions requiring treatment
- Patients with in-stent restenosis in a lesion requiring treatment
- Patients with bifurcation lesions requiring stenting in lateral branches
- Patients with lesions requiring more than 3 stents
Key Trial Info
Start Date :
December 15 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 17 2022
Estimated Enrollment :
1452 Patients enrolled
Trial Details
Trial ID
NCT03447379
Start Date
December 15 2017
End Date
August 17 2022
Last Update
March 12 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Gangnam Severance Hospital
Seoul, Souel, South Korea